<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052728</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258720</org_study_id>
    <secondary_id>NCI-03-C-0037</secondary_id>
    <secondary_id>NCI-5540</secondary_id>
    <nct_id>NCT00052728</nct_id>
    <nct_alias>NCT00048867</nct_alias>
  </id_info>
  <brief_title>Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for tumor cell growth. Tamoxifen may fight breast cancer by blocking the use of estrogen.&#xD;
      Combining tipifarnib with tamoxifen may be effective treatment for metastatic breast cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving tipifarnib together with tamoxifen&#xD;
      works in treating women with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of tipifarnib&#xD;
           administered with tamoxifen in women with hormone receptor-positive metastatic breast&#xD;
           cancer (Phase I closed to accrual effective 10/23/2003).&#xD;
&#xD;
        -  Determine the acute and chronic toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the response rate and time to progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label study of tipifarnib (Phase I closed to accrual effective&#xD;
      10/23/2003). Patients are stratified according to benefit from prior hormonal therapy (yes vs&#xD;
      no) (phase II).&#xD;
&#xD;
        -  Phase I (closed to accrual effective 10/23/2003): Patients receive oral tipifarnib twice&#xD;
           daily on days 1-21. Patients also receive oral tamoxifen daily on days 8-18 (during&#xD;
           course I only) and on days 1-28 during all subsequent courses. Courses repeat every 28&#xD;
           days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of tipifarnib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Once the MTD is determined, additional patients are accrued and treated at&#xD;
           that dose level in the phase II portion of the study.&#xD;
&#xD;
      Patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-12 patients will be accrued for the phase I portion of this&#xD;
      study (Phase I closed to accrual effective 10/23/2003). A total of 27-40 patients will be&#xD;
      accrued for the phase II portion of this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic (stage IV) breast cancer&#xD;
&#xD;
          -  Evidence of disease progression&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Must have been previously treated with at least 1 hormonal therapy with either an&#xD;
             aromatase inhibitor or an estrogen receptor (ER)-modulating drug in the adjuvant or&#xD;
             metastatic setting and meets 1 of the following criteria:&#xD;
&#xD;
               -  Hormone-responsive disease:&#xD;
&#xD;
                    -  Stable disease (no recurrence or progression for at least 6 months)&#xD;
&#xD;
                    -  Objective response&#xD;
&#xD;
               -  Hormone-nonresponsive disease:&#xD;
&#xD;
                    -  No stable disease&#xD;
&#xD;
                    -  No objective response&#xD;
&#xD;
          -  Previously treated CNS disease allowed provided patient has a life expectancy of at&#xD;
             least 3 months (phase I patients) (Phase I closed to accrual effective 10/23/2003)&#xD;
&#xD;
          -  No CNS metastases (phase II patients)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  ER and/or progesterone receptor positive&#xD;
&#xD;
          -  NOTE: As few as 1% positive cells considered positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (unless evidence of Gilbert's disease)&#xD;
&#xD;
          -  SGOT and SGPT less than 3 times upper limit of normal (unless liver involvement by&#xD;
             tumor)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception during and for 2 months&#xD;
             after study participation&#xD;
&#xD;
          -  No medical or psychiatric condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for metastatic disease (phase II patients)&#xD;
&#xD;
               -  No limitations on prior neoadjuvant or adjuvant regimens&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior tamoxifen&#xD;
&#xD;
          -  Concurrent stable dose of steroids allowed (phase I patients) (Phase I closed to&#xD;
             accrual effective 10/23/2003)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Concurrent surgery allowed provided the need for surgery is not due to disease&#xD;
             progression&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior warfarin&#xD;
&#xD;
          -  No concurrent cytochrome p450-inducing anti-convulsants&#xD;
&#xD;
          -  No other concurrent anticancer therapies&#xD;
&#xD;
          -  Concurrent bisphosphonates for bone metastases allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JoAnne Zujewski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lebowitz PF, Eng-Wong J, Widemann BC, Balis FM, Jayaprakash N, Chow C, Clark G, Gantz SB, Venzon D, Zujewski J. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res. 2005 Feb 1;11(3):1247-52.</citation>
    <PMID>15709195</PMID>
  </results_reference>
  <results_reference>
    <citation>Lebowitz PF, Eng-Wong J, Balis F, et al.: A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 22 (Suppl 14): A-644, 38s, 2004.</citation>
  </results_reference>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

